SIOUX FALLS, 12/13/11— pharmaCline™ has been nominated for the 2012 Edison Awards.  The Edison Awards recognize and honor innovation and excellence in the development, marketing and launch of new products. The Edison Awards Steering Committee has recognized the company’s Diabecline® antibiotic, in combination with Site Specific Penetration Technology™, as a 2012 Edison Award Nominee for Best New Product.  The Edison Awards are the premier awards recognizing innovation excellence in the spirit of the accomplishments of early inventors. For more information on the Edison Awards visit http://edisonawards.com/.

“We are honored to be a nominee for this prestigious award,” said pharmaCline CEO Steve Keough.

Diabecline antibiotic is a game-changing first aid antibiotic that is available over-the-counter to help prevent infection.  This product is non-allergenic and suitable for use by a wide range of people. pharmaCline antibiotics restore the effective use of old and well known classes of active pharmaceuticals. Site Specific Penetration Technology unleashes the power of hope to millions of people with chronic infections and other maladies.  Using this technology, multiple antibiotic products have been developed at a fraction of the usual cost and time of pharmaceutical development. This directly contributes to the restoration of health and productivity to patients worldwide. pharmaCline products and information are available at http://www.pharmacline.com.

Contact Information:

Lana McCoy, Executive Marketing Coordinator

Email: lmccoy@pharmacline.com

Phone: 605-271-2086

2329 N. Career Avenue, Suite 243

Sioux Falls, SD 57107

www.pharmacline.com